Researchers at the Lewis Katz School of Medicine at Temple University announced in a Late-Breaking Innovation Session at the 2022 Transcatheter Cardiovascular Therapeutics conference that the BASHIR™ Endovascular Catheter significantly reduces the size of blood clots lodged in pulmonary arteries, leading to improvement in heart function in patients with pulmonary embolism. The breakthrough is also described in a report published in the Journal of the American College of Cardiology: Cardiovascular Interventions. Riyaz Bashir, MD, FACC, Professor of Medicine at the Katz School of Medicine and Director of Vascular and Endovascular Medicine at Temple University Hospital, is the co-inventor of the catheter. Dr. Bashir conducted a video interview with Clinical Trial Results about the catheter and the RESCUE trial, a clinical study designed to evaluate the safety and efficacy of the catheter as a novel therapy for pulmonary embolism. The American College of Cardiology, Scienmag, the Science Times and HospiMedica.com also highlighted the news. Parth Rali, MD, Associate Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine and Director of the Temple University Health System Pulmonary Embolism Response Team (PERT), is the local principal investigator on the RESCUE trial. Vladimir Lakhter, DO, Assistant Professor of Medicine at the Lewis Katz School of Medicine and an interventional cardiologist, is also involved in the RESCUE trial.